Application of recombinant human interleukin-11 (rhIL-11) for acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2009.02.007
- VernacularTitle:重组人白细胞介素-11在16例急性髓系白血病化疗中的应用
- Author:
Zujun JIANG
;
Yang XIAO
;
Haowen XIAO
;
Yang GAO
- Publication Type:Journal Article
- Keywords:
Interleukin-11;
Leukemia,myelocytic,acute;
Antineoplastic combined chemotherapy protocols;
Thrombocytopenia
- From:
Journal of Leukemia & Lymphoma
2009;18(2):86-87
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effect and adverse effect for chemthrombocytopenic of rhIL-11 in chemotherapy for acute myeloid leukemia. Methods We adopted a randomized, blank-control, crossover trial of rhIL-11 in 16 newly diagnosed patients with acute myeloid leukemia. The treatment group were accepted chemotherapy by DA or TA. rhIL-11 (25μg·kg-1·d-1, subcutaneously) was administered from 24 h after chemotherapy and continued for seven to fourteen days. The changes of platelet counts were observed. Results The group by chemotherapy had higher platelet counts than control after rhIL-11 treatment and platelet transfusion frequency was reduced. The adverse effect of rhIL-11 was light, including fatigue, muscular soreness and low-grade fever. Conclusion rhIL-11 is safe and effective in reducing chemotherapy thrombocytopenia.
